According to Benzinga Pro, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.87%, ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

BofA raised the firm’s price target on Alnylam (ALNY) to $328 from $325 and keeps a Buy rating on the shares. The firm updated models in ...

CAMBRIDGE, Mass., April 17, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG. Click here to ...

As tariff threats and FDA staff cuts thrust the biopharma world into uncharted waters, President Donald Trump is offering the ...

A recent selloff of Neurocrine Biosciences stock feels unwarranted and may have created a contrarian buy opportunity. Learn ...

Vir Biotechnology, Inc.’s VIR share price has surged by 5.82%, which has investors questioning if this is right time to sell.